Table 2.

MGMT promoter methylation, 1p/19q deletion, and clinical outcome of surgically resected pulmonary carcinoid and LCNEC

Patient	1p Del	19q Del	MGMTMet	Metastasis (ML)	DFS (mon)	OS (mon)
1	No	Yes	No	Yes (TV)	10	36
2	Yes	No	No	Yes (B)	29	29
3	No	Yes	Yes	No	22	22
4	No	No	No	No	41	41
5	Yes	No	Yes	Yes (B)	12	44
6	Yes	No	No	Yes (CV; DOD)	9	34
7	No	No	–	No	112	112
8	No	No	No	No	107	107
9	Yes	No	No	No	101	101
10	No	Yes	–	No	84	84
11	No	No	No	No	37	37
12	Yes	No	No	No	31	31
13	No	No	No	No	51	51
14	No	No	–	No	38	38
15	No	Yes	No	No	11	11

LCNEC large-cell neuroendocrine carcinoma, Del deletion, Met methylation, ML metastatic lesions when the first metastasis occurred, B brain, TV thoracic vertebra, CV cervical vertebra, DOD dead of disease, DFS disease-free survival, OS overall survival